Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...
Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...
Archbow Consulting announced Justine Hughes has been promoted to EVP of principal operations while Honora Gabriel and Rob ...
Hosted on MSN1d
Amgen price target lowered to $295 from $310 at CitiCiti lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...
In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities. Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an ...
BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
Dr. Jordan accepted a position with Eli Lilly and Co., Agricultural Research Division in Greenfield, Indiana on June 1, 1959, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback